Lipids [BR:br08002]
PK Polyketides
PK13 Aromatic polyketides
PK1312 Other aromatic polyketides
C07578 Cannabidiol
Phytochemical compounds [BR:br08003]
Polyketides
Others
Cannabinoids
C07578 Cannabidiol
Secondary metabolites in pathway maps [br08011.html]
Biosynthetic pathways and modules of secondary metabolites
C07578
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AX Other antiepileptics
N03AX24 Cannabidiol
D10915 Cannabidiol (JAN/USAN/INN) <US>
USP drug classification [BR:br08302]
Anticonvulsants
Anticonvulsants, Other
Cannabidiol
D10915 Cannabidiol (JAN/USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
D10915 Cannabidiol
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D10915 Cannabidiol
DG02924 UGT substrate
DG03185 UGT1A7 substrate
D10915 Cannabidiol
DG03188 UGT1A9 substrate
D10915 Cannabidiol
DG03190 UGT2B7 substrate
D10915 Cannabidiol
Transporter substrate
DG01665 ABCB1 substrate
D10915 Cannabidiol
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Cannabinoid
CNR
D10915 Cannabidiol (JAN/USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10915
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10915
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10915
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10915
Drug transporters
D10915
Narcotics and psychotropics in Japan [br08308.html]
Opium and Cannabis
D10915
